1α,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases

Carcinogenesis

Volumn 27, Issue 1, 2006, Pages 32-42

  Bao, Bo Ying ^a,b   Yeh, Shauh Der ^c   Lee, Yi Fen ^a  

^a UNIVERSITY OF ROCHESTER   (United States)

^b University of Rochester   (United States)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITRIOL; CATHEPSIN; ENZYME INHIBITOR; GELATINASE B; MATRIX METALLOPROTEINASE; MESSENGER RNA; PLASMINOGEN ACTIVATOR; PROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSCRIPTION FACTOR AP 1; VITAMIN D DERIVATIVE; DIHYDROXY VITAMIN D3; DIHYDROXY-VITAMIN D3; DRUG DERIVATIVE; VITAMIN D;

ADVANCED CANCER; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INVASION; CELL ASSAY; CELL STRAIN LNCAP; COMPLEX FORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MODULATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROTEIN BINDING; PROTEIN EXPRESSION; RNA STABILITY; CELL CULTURE; CELL MOTION; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PROSTATE TUMOR;

CATHEPSINS; CELL MOVEMENT; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; PLASMINOGEN ACTIVATORS; PROMOTER REGIONS (GENETICS); PROSTATIC NEOPLASMS; RNA, MESSENGER; TISSUE INHIBITOR OF METALLOPROTEINASE-1; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; VITAMIN D;

EID: 29744463149     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgi170     Document Type: Article

References (68)

1. Meyer,T. and Hart,I.R. (1998) Mechanisms of tumour metastasis. Eur. J. Cancer, 34, 214-221.
2. Chambers,A.F. and Matrisian,L.M. (1997) Changing views of the role of matrix metalloproteinases in metastasis. J. Natl Cancer Inst., 89, 1260-1270.
3. Stetler-Stevenson,W.G., Hewitt,R. and Corcoran,M. (1996) Matrix metalloproteinases and tumor invasion: From correlation and causality to the clinic. Semin. Cancer Biol., 7, 147-154.
4. Bernhard,E.J., Gruber,S.B. and Muschel,R.J. (1994) Direct evidence linking expression of matrix metalloproteinase 9 (92-kDa gelatinase/ collagenase) to the metastatic phenotype in transformed rat embryo cells. Proc. Natl Acad. Sci. USA, 91, 4293-4297.
5. Zucker,S., Lysik,R.M., Zarrabi,M.H. and Moll,U. (1993) M(r) 92,000 type IV collagenase is increased in plasma of patients with colon cancer and breast cancer. Cancer Res., 53, 140-146.
6. Mook, O.R., Frederiks,W.M. and Van Noorden,C.J. (2004) The role of gelatinases in colorectal cancer progression and metastasis. Biochim. Biophys. Acta, 1705, 69-89.
7. Dano,K., Andreasen,P.A., Grondahl-Hansen,J., Kristensen,P., Nielsen,L.S. and Skriver,L. (1985) Plasminogen activators, tissue degradation, and cancer. Adv. Cancer Res., 44, 139-266.
8. Laiho,M. and Keski-Oja,J. (1989) Growth factors in the regulation of pericellular proteolysis: A review. Cancer Res., 49, 2533-2553.
9. Holst-Hansen,C., Johannessen,B., Hoyer-Hansen,G., Romer,J., Ellis,V. and Brunner,N. (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin. Exp. Metastasis, 14, 297-307.
10. Grondahl-Hansen,J., Christensen,I.J., Rosenquist,C., Brunner,N., Mouridsen,H.T., Dano,K. and Blichert-Toft,M. (1993) High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res., 53, 2513-2521.
11. Castiglioni,T., Merino,M.J., Elsner,B., Lah,T.T., Sloane,B.F. and Emmert-Buck,M.R. (1994) Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum. Pathol., 25, 857-862.
12. Poole,A.R., Tiltman,K.J., Recklies,A.D. and Stoker,T.A. (1978) Differences in secretion of the proteinase cathepsin B at the edges of human breast carcinomas and fibroadenomas. Nature, 273, 545-547.
13. Sinha,A.A., Wilson,M.J., Gleason,D.F., Reddy,P.K., Sameni,M. and Sloane,B.F. (1995) Immunohistochemical localization of cathepsin B in neoplastic human prostate. Prostate, 26, 171-178.
14. Sloane,B.F., Dunn,J.R. and Honn,K.V. (1981) Lysosomal cathepsin B: correlation with metastatic potential. Science, 212, 1151-1153.
15. Page,A.E., Warburton,M.J., Chambers,T.J., Pringle,J.A. and Hayman,A.R. (1992) Human osteoclastomas contain multiple forms of cathepsin B. Biochim. Biophys. Acta, 1116, 57-66.
16. Guinec,N., Dalet-Fumeron,V. and Pagano,M. (1993) In vitro study of basement membrane degradation by the cysteine proteinases, cathepsins B, B-like and L. Digestion of collagen IV, laminin, fibronectin, and release of gelatinase activities from basement membrane fibronectin. Biol. Chem. Hoppe Seyler., 374, 1135-1146.
17. Lah,T.T., Buck,M.R., Honn,K.V., Crissman,J.D., Rao,N.C., Liotta,L.A. and Sloane,B.F. (1989) Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis, 7, 461-468.
18. Mason,R.W., Johnson,D.A., Barrett,A.J. and Chapman,H.A. (1986) Elastinolytic activity of human cathepsin L. Biochem. J., 233, 925-927.
19. Kastelic,L., Turk,B., Kopitar-Jerala,N., Stolfa,A., Rainer,S., Turk,V. and Lah,T.T. (1994) Stefin B, the major low molecular weight inhibitor in ovarian carcinoma. Cancer Lett., 82, 81-88.
20. Lah,T.T., Clifford,J.L., Helmer,K.M., Day,N.A., Moin,K., Honn,K.V., Crissman,J.D. and Sloane,B.F. (1989) Inhibitory properties of low molecular mass cysteine proteinase inhibitors from human sarcoma. Biochim. Biophys. Acta, 993, 63-73.
21. Kolar,Z., Jarvinen,M. and Negrini,R. (1989) Demonstration of proteinase inhibitors cystatin A, B and C in breast cancer and in cell lines MCF-7 and ZR-75-1. Neoplasma, 36, 185-189.
22. Hanchette,C.L. and Schwartz,G.G. (1992) Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. Cancer, 70, 2861-2869.
23. Schwartz,G.G. and Hulka,B.S. (1990) Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res., 10, 1307-1311.
24. Young,M.R., Halpin,J., Hussain,R., Lozano,Y., Djordjevic,A., Devata,S., Matthews,J.P. and Wright,M.A. (1993) Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion Metastasis, 13, 169-177.
25. Schwartz,G.G., Wang,M.H., Zang,M., Singh,R.K. and Siegal,G.P. (1997) 1 alpha,25-Dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev., 6, 727-7132.
26. Hansen,C.M., Frandsen,T.L., Brunner,N. and Binderup,L. (1994) 1 alpha,25-Dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin. Exp. Metastasis, 12, 195-202.
27. Konety,B.R., Lavelle,J.P., Pirtskalaishvili,G. et al. (2001) Effects of vitamin D (calcitriol) on transitional cell carcinoma of the bladder in vitro and in vivo. J. Urol., 165, 253-258.
28. Beer,T.M., Eilers,K.M., Garzotto,M., Egorin,M.J., Lowe,B.A. and Henner,W.D. (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. J. Clin. Oncol., 21, 123-128.
29. Beer,T.M., Eilers,K.M., Garzotto,M., Hsieh,Y.C. and Mori,M. (2004) Quality of life and pain relief during treatment with calcitriol and docetaxel in symptomatic metastatic androgen-independent prostate carcinoma. Cancer, 100, 758-763.
30. Koli,K. and Keski-Oja,J. (2000) 1alpha,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Differ., 11, 221-229.
31. Friberger,P., Knos,M., Gustavsson,S., Aurell,L. and Claeson,G. (1978) Methods for determination of plasmin, antiplasmin and plasminogen by means of substrate S-2251. Haemostasis, 7, 138-145.
32. Mayer,P., Schmid,H., Schaber,B. and Fierlbeck,G. (1997) Tumor-associated cysteine proteinase activities in human melanoma cells and fibroblasts of different origin. Eur. J Cell. Biol., 73, 344-351.
33. Kirschke,H., Wood,L., Roisen,F.J. and Bird,J.W. (1983) Activity of lysosomal cysteine proteinase during differentiation of rat skeletal muscle. Biochem. J., 214, 871-877.
34. Kato,Y., Yamashita,T. and Ishikawa,M. (2002) Relationship between expression of matrix metalloproteinase-2 and matrix metalloproteinase-9 and invasion ability of cervical cancer cells. Oncol. Rep., 9, 565-569.
35. Ottino,P., Taheri,F. and Bazan,H.E. (2002) Platelet-activating factor induces the gene expression of TIMP-1, -2, and PAI-1: Imbalance between the gene expression of MMP-9 and TIMP-1 and -2. Exp. Eye Res., 74, 393-402.
36. Castello,R., Estelles,A., Vazquez,C., Falco,C., Espana,F., Almenar,S.M., Fuster,C. and Aznar,J. (2002) Quantitative real-time reverse transcription-PCR assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1, and tissue metalloproteinase inhibitor type 1 gene expressions in primary breast cancer. Clin. Chem., 48, 1288-1295.
37. Grigolo,B., Roseti,L., Fiorini,M., Piacentini,A., De Franceschi,L. and Facchini,A. (2003) Cathepsin B as a soluble marker to monitor the phenotypic stability of engineered cartilage. Biomaterials, 24, 1751-1757.
38. Guttentag,S., Robinson,L., Zhang,P., Brasch,F., Buhling,F. and Beers,M. (2003) Cysteine protease activity is required for surfactant protein B processing and lamellar body genesis. Am. J. Respir. Cell Mol. Biol., 28, 69-79.
39. Alevizos,I., Mahadevappa, M., Zhang,X. et al. (2001) Oral cancer in vivo gene expression profiling assisted by laser capture microdissection and microarray analysis. Oncogene, 20, 6196-6204.
40. Livak,K.J. and Schmittgen,T.D. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 25, 402-408.
41. Clark,I.M., Rowan,A.D., Edwards,D.R., Bech-Hansen,T., Mann,D.A., Bahr,M.J. and Cawston,T.E. (1997) Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1. Biochem. J., 324, 611-617.
42. Andrews,N.C. and Faller,D.V. (1991) A rapid micropreparation technique for extraction of DNA-binding proteins from limiting numbers of mammalian cells. Nucleic Acids Res., 19, 2499.
43. Bao,B.Y., Hu,Y.C., Ting,H.J. and Lee,Y.F. (2004) Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells. Oncogene, 23, 3350-3360.
44. Ly,L.H., Zhao,X.Y., Holloway,L. and Feldman,D. (1999) Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology, 140, 2071-2076.
45. Skowronski,R.J., Peehl,D.M. and Feldman,D. (1993) Vitamin D and prostate cancer: 1,25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology, 132, 1952-1960.
46. Barrett,A.J. and Kirschke,H. (1981) Cathepsin B, Cathepsin H, and cathepsin L. Methods Enzymol., 80 Pt C, 535-561.
47. Beer,T.M. and Myrthue,A. (2004) Calcitriol in cancer treatment: From the lab to the clinic. Mol. Cancer Ther., 3, 373-381.
48. Mantell,D.J., Owens,P.E., Bundred,N.J., Mawer,E.B. and Canfield,A.E. (2000) 1 alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circ Res., 87, 214-220.
49. Lacraz,S., Dayer,J.M., Nicod,L. and Welgus,H.G. (1994) 1,25-dihydroxyvitamin D3 dissociates production of interstitial collagenase and 92-kDa gelatinase in human mononuclear phagocytes. J. Biol. Chem., 269, 6485-6490.
50. Sato,H. and Seiki,M. (1993) Regulatory mechanism of 92 kDa type IV collagenase gene expression which is associated with invasiveness of tumor cells. Oncogene, 8, 395-405.
51. Gum,R., Wang,H., Lengyel,E., Juarez,J. and Boyd,D. (1997) Regulation of 92 kDa type IV collagenase expression by the jun aminoterminal kinase-and the extracellular signal-regulated kinase-dependent signaling cascades. Oncogene, 14, 1481-1493.
52. Liu,P., Kimmoun,E., Legrand,A., Sauvanet,A., Degott,C., Lardeux,B. and Bernuau,D. (2002) Activation of NF-kappa B, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J. Hepatol., 37, 63-71.
53. Zeigler,M.E., Chi,Y., Schmidt,T. and Varani,J. (1999) Role of ERK and JNK pathways in regulating cell motility and matrix metalloproteinase 9 production in growth factor-stimulated human epidermal keratinocytes. J. Cell Physiol., 180, 271-284.
54. Hozumi,A., Nishimura,Y., Nishiuma,T., Kotani,Y. and Yokoyama,M. (2001) Induction of MMP-9 in normal human bronchial epithelial cells by TNF-alpha via NF-kappa B-mediated pathway. Am J Physiol Lung Cell Mol Physiol., 281, L1444-L1452.
55. Yu,X.P., Bellido,T. and Manolagas,S.C. (1995) Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proc. Natl Acad. Sci. USA, 92, 10990-10994.
56. Harant,H., Wolff, B. and Lindley,I.J. (1998) 1Alpha,25-dihydroxyvitamin D3 decreases DNA binding of nuclear factor-kappaB in human fibroblasts. FEBS Lett, 436, 329-334.
57. Gyetko,M.R., Webb,A.C. and Sitrin,R.G. (1988) Modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2 expression by U-937 mononuclear phagocytes. Effects of 1 alpha, 25-dihydroxyvitamin D3 and phorbol ester. J. Immunol., 141, 2693-2698.
58. Fukumoto,S., Allan,E.H. and Martin,T.J. (1994) Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochim. Biophys. Acta, 1201, 223-228.
59. Koli,K. and Keski-Oja,J. (1993) Vitamin D3 and calcipotriol decrease extracellular plasminogen activator activity in cultured keratinocytes. J. Invest. Dermatol., 101, 706-712.
60. Verde,P., Boast,S., Franze,A., Robbiati,F. and Blasi,F. (1988) An upstream enhancer and a negative element in the 5′ flanking region of the human urokinase plasminogen activator gene. Nucleic Acids Res., 16, 10699-10716.
61. Hoosein,N.M., Boyd,D.D., Hollas,W.J., Mazar,A., Henkin,J. and Chung,L.W. (1991) Involvement of urokinase and its receptor in the invasiveness of human prostatic carcinoma cell lines. Cancer Commun., 3, 255-264.
62. Simboli-Campbell,M., Narvaez,C.J., van Weelden,K., Tenniswood,M. and Welsh,J. (1997) Comparative effects of 1,25(OH)2D3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res. Treat., 42, 31-41.
63. Atkins,K.B. and Troen,B.R. (1995) Regulation of cathepsin D gene expression in HL-60 cells by retinoic acid and calcitriol. Cell Growth Differ., 6, 871-877.
64. Lin,R., Nagai,Y., Sladek,R., Bastien,Y., Ho,J., Petrecca,K., Sotiropoulou,G., Diamandis,E.P., Hudson,T.J. and White,J.H. (2002) Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol., 16, 1243-1256.
65. Takahashi,H., Ibe,M., Honma,M., Ishida-Yamamoto,A., Hashimoto,Y. and Iizuka,H. (2003) 1,25-dihydroxyvitamin D(3) increases human cystatin A expression by inhibiting the Raf-1/MEK1/ERK signaling pathway of keratinocytes. Arch. Dermatol. Res., 295, 80-87.
66. Alvarez,O.A., Carmichael,D.F. and DeClerck,Y.A. (1990) Inhibition of collagenolytic activity and metastasis of tumor cells by a recombinant human tissue inhibitor of metalloproteinases. J. Natl. Cancer Inst., 82, 589-595.
67. Chen,A., Davis,B.H., Bissormette,M., Scaglione-Sewell,B. and Brasitus,T.A. (1999) 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. J. Biol. Chem., 274, 35505-35513.
68. Yeung,F., Law,W.K., Yeh,C.H., Westendorf,J.J., Zhang,Y., Wang,R., Kao,C. and Chung,L.W. (2002) Regulation of human osteocalcin promoter in hormone-independent human prostate cancer cells. J. Biol. Chem., 277, 2468-2476.